Showing items 1 - 2 of 2

Rationale and Design of the Cessation Of Pharmacotherapy In Recovered Chemotherapy-induced cardioToxicity (COP-RCT): A Pilot Study

- Yu, Christopher, Negishi, Tomoko, Pathan, Faraz, Sverdlov, Aaron, Thomas, Liza, Shirazi, Mitra, Koo, Chieh Yang, Tan, Li Ling, Miyazaki, Sakiko, Negishi, Kazuaki

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

- Lyon, Alexander R., Dent, Susan, Stanway, Susannah, Earl, Helena, Brezden-Masley, Christine, Cohen-Solal, Alain, Tocchetti, Carlo G., Moslehi, Javid J., Groarke, John D., Bergler-Klein, Jutta, Khoo, Vincent, Tan, Li Ling, Anker, Markus S., von Haehling, Stephan, Maack, Christoph, Pudil, Radek, Barac, Ana, Thavendiranathan, Paaladinesh, Ky, Bonnie, Neilan, Tomas G., Sverdlov, Aaron L.

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit